Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma.

Fang HY, Münch NS, Schottelius M, Ingermann J, Liu H, Schauer M, Stangl S, Multhoff G, Steiger K, Gerngroß C, Jesinghaus M, Weichert W, Kühl AA, Sepulveda AR, Wester HJ, Wang TC, Quante M.

Clin Cancer Res. 2018 Mar 1;24(5):1048-1061. doi: 10.1158/1078-0432.CCR-17-1756. Epub 2017 Dec 5.

2.

Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.

Bobryshev YV, Freeman AK, Botelho NK, Tran D, Levert-Mignon AJ, Lord RV.

Dis Esophagus. 2010 Sep;23(7):580-9. doi: 10.1111/j.1442-2050.2010.01061.x. Epub 2010 Apr 29.

PMID:
20459440
3.

Barrett's esophagus and Barrett's-related dysplasia.

Goldblum JR.

Mod Pathol. 2003 Apr;16(4):316-24. Review.

4.

The diagnosis and management of Barrett's esophagus.

DeMeester SR, DeMeester TR.

Adv Surg. 1999;33:29-68. Review.

PMID:
10572561
5.

Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV.

Am J Gastroenterol. 2005 Jun;100(6):1257-64.

PMID:
15929754
6.

Endoscopic Raman spectroscopy enables objective diagnosis of dysplasia in Barrett's esophagus.

Almond LM, Hutchings J, Lloyd G, Barr H, Shepherd N, Day J, Stevens O, Sanders S, Wadley M, Stone N, Kendall C.

Gastrointest Endosc. 2014 Jan;79(1):37-45. doi: 10.1016/j.gie.2013.05.028. Epub 2013 Jul 22.

PMID:
23886354
7.

Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.

Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM.

Mod Pathol. 2009 Dec;22(12):1612-21. doi: 10.1038/modpathol.2009.133. Epub 2009 Sep 4.

8.

Barrett's esophagus and risk of esophageal adenocarcinoma.

Cossentino MJ, Wong RK.

Semin Gastrointest Dis. 2003 Jul;14(3):128-35. Review.

PMID:
14653412
9.

Barrett's surveillance identifies patients with early esophageal adenocarcinoma.

Wong T, Tian J, Nagar AB.

Am J Med. 2010 May;123(5):462-7. doi: 10.1016/j.amjmed.2009.10.013.

PMID:
20399324
10.

Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.

Canto MI, Setrakian S, Willis JE, Chak A, Petras RE, Sivak MV.

Endoscopy. 2001 May;33(5):391-400.

PMID:
11396755
11.

Surveillance in Barrett's esophagus: an audit of practice.

Ajumobi A, Bahjri K, Jackson C, Griffin R.

Dig Dis Sci. 2010 Jun;55(6):1615-21. doi: 10.1007/s10620-009-0917-y. Epub 2009 Aug 11.

PMID:
19669878
12.

Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.

Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5. doi: 10.1158/1055-9965.EPI-07-2734.

13.

A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.

Ahmad J, Arthur K, Maxwell P, Kennedy A, Johnston BT, Murray L, McManus DT.

Dis Esophagus. 2015 Apr;28(3):276-82. doi: 10.1111/dote.12181. Epub 2014 Feb 25.

PMID:
24612412
14.

Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.

Brabender J, Lord RV, Wickramasinghe K, Metzger R, Schneider PM, Park JM, Hölscher AH, DeMeester TR, Danenberg KD, Danenberg PV.

J Gastrointest Surg. 2002 May-Jun;6(3):359-67.

PMID:
12022988
15.

MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.

Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X.

Clin Cancer Res. 2009 Sep 15;15(18):5744-52. doi: 10.1158/1078-0432.CCR-09-0385. Epub 2009 Sep 8.

16.

Dendritic cells in Barrett's esophagus and esophageal adenocarcinoma.

Bobryshev YV, Tran D, Killingsworth MC, Buckland M, Lord RV.

J Gastrointest Surg. 2009 Jan;13(1):44-53. doi: 10.1007/s11605-008-0613-9. Epub 2008 Aug 7.

PMID:
18685901
17.

Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.

Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K, Haggitt RC, Dean PJ, Thor K, Rabinovitch PS.

Gastroenterology. 1992 Apr;102(4 Pt 1):1220-8.

PMID:
1551529
18.

Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.

Wang DH, Clemons NJ, Miyashita T, Dupuy AJ, Zhang W, Szczepny A, Corcoran-Schwartz IM, Wilburn DL, Montgomery EA, Wang JS, Jenkins NA, Copeland NA, Harmon JW, Phillips WA, Watkins DN.

Gastroenterology. 2010 May;138(5):1810-22. doi: 10.1053/j.gastro.2010.01.048. Epub 2010 Feb 4.

19.

EUS in the management of the patient with dysplasia in Barrett's esophagus.

Savoy AD, Wallace MB.

J Clin Gastroenterol. 2005 Apr;39(4):263-7. Review.

PMID:
15758616
20.

Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV.

J Gastrointest Surg. 2000 Mar-Apr;4(2):135-42.

PMID:
10675236

Supplemental Content

Support Center